humira ac (adalimumab) 40 mg / 0,4 ml solucion inyectable jeringa prellenada
farmaceutica a&m, c.a. - adalimumab - solucion - 40 mg / 0,4 ml
humira (adalimumab) 40 mg / 0,8 ml solucion inyectable frasco ampolla
abbvie pharmaceuticals s.c.a. - adalimumab - solucion - 40 mg / 0,8 ml
yervoy
bristol-myers squibb pharma eeig - el ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agentes antineoplásicos - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 y 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
keytruda (pembrolizumab) 100 mg / 4 ml concentrado para solucion para infusion
msd farmaceutica, c.a. - pembrolizumab - solucion para infusion - 100 mg / 4 ml
yervoy solución inyectable 200 mg/40 ml (ipilimumab)
bristol - myers squibb de chile - ipilimumab - sin formulas
simponi® 12.5 mg/1ml solucion inyectable
j&j productos medicos & farmaceuticos del peru s.a. - droguerÍa - golimumab - solucion inyectable - 12.5mg/1ml - por vial 4.00 ml - - golimumab
benlysta 120 mg polvo para concentrado para solucion para perfusion
glaxosmithkline peru s.a. - belimumab; - polvo para concentrado para solucion para perfusion - por vial2 ml; belimumab 120.000000 mg; - belimumab
benlysta 400 mg polvo para concentrado para solucion para perfusion
glaxosmithkline peru s.a. - belimumab; - polvo para concentrado para solucion para perfusion - por vial5 ml; belimumab 400.000000 mg; - belimumab
humira 40mg/0.8 ml solución inyectable
abbvie sas, sucursal del peru - droguerÍa - adalimumab - solución inyectable - 40mg/0.8 ml - por mililitro 0.80 ml - - adalimumab